Amicus Therapeutics (NASDAQ:FOLD) Upgraded at StockNews.com

StockNews.com upgraded shares of Amicus Therapeutics (NASDAQ:FOLD) from a hold rating to a buy rating in a research note released on Wednesday morning.

Other research analysts also recently issued reports about the company. Guggenheim lifted their price target on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, November 7th. JPMorgan Chase & Co. boosted their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Bank of America boosted their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research note on Thursday, October 17th. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research note on Monday, January 13th. Finally, Morgan Stanley restated an “equal weight” rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.88.

Amicus Therapeutics Trading Up 1.3 %

Shares of NASDAQ:FOLD opened at $9.77 on Wednesday. Amicus Therapeutics has a 12-month low of $8.78 and a 12-month high of $14.03. The business’s fifty day simple moving average is $9.60 and its 200-day simple moving average is $10.43. The company has a market capitalization of $2.92 billion, a PE ratio of -28.74, a P/E/G ratio of 1.69 and a beta of 0.61. The company has a current ratio of 3.15, a quick ratio of 2.42 and a debt-to-equity ratio of 2.18.

Insiders Place Their Bets

In other news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $10.02, for a total value of $75,150.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at $8,884,273.08. The trade was a 0.84 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 2.20% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amicus Therapeutics

A number of large investors have recently bought and sold shares of FOLD. Ameritas Investment Partners Inc. increased its stake in Amicus Therapeutics by 4.4% during the 4th quarter. Ameritas Investment Partners Inc. now owns 30,696 shares of the biopharmaceutical company’s stock worth $289,000 after buying an additional 1,280 shares in the last quarter. Hazlett Burt & Watson Inc. increased its stake in Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,569 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Amicus Therapeutics by 21.3% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,727 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 1,884 shares in the last quarter. Xponance Inc. increased its stake in Amicus Therapeutics by 11.9% during the 4th quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 2,249 shares in the last quarter. Finally, Covestor Ltd increased its stake in Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company’s stock worth $41,000 after buying an additional 2,312 shares in the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.